Russian researchers come up with faster method to discover antibiotics

Russian biochemists have identified a promising new class of antibiotics. Having studied over 125,000 molecules, they found that 2-pyrazol-1-yl-thiazole derivatives exhibit antibacterial properties. One of the discovered compounds has demonstrated a good activity and low cytotoxicity, and thus can serve as a prototype in further studies. The paper was published in The Journal of Antibiotics.

The development of antibiotics is one of the key discoveries of the 20th century. Today's world is almost unimaginable without them. However, the rise of antibiotic resistance in bacteria -- that is, their acquired ability to withstand the effects of drugs -- creates a constant need for new drugs. New studies may take years and are hence becoming unprofitable for pharmaceutical companies. This is why novel methods for discovering new classes of antibiotic drugs are of the essence.

The development of new antibacterial drugs designed to overcome the resistance of clinically important bacterial strains has attracted considerable scientific and social interest. However, this process is mostly focused on identifying structural analogs within the already known antibiotic classes. We, on the contrary, think that discovering new chemotypes is more effective in the search for antibacterial drugs."

Anastasia Aladinskaya, researcher, Laboratory of Medical Chemistry and Bioinformatics, Moscow Institute of Physics and Technology (MIPT) and  study co-author

Researchers from MIPT and their colleagues from Skoltech, Lomonosov Moscow State University, and the Russian Academy of Sciences Institute of Biochemistry and Genetics in Ufa, devised and applied a semi-automatic analysis method and used a nonresistant strain of the Escherichia coli bacteria as a model organism. The method relies on bacterial activity control and clearly shows the mechanism of action of different compounds. There are a number of ways to kill bacteria. In this study, the scientists looked for either of the two: abnormalities in the bacteria's genetic material -- their DNA -- or protein synthesis inhibition. Given that the method is quite simple and can be automated, the scientists were able to study over 125,000 molecules.

"Together with our colleagues, the MIPT lab performed high-throughput screening of small-molecule libraries to identify structurally diverse compounds with antibacterial activity. The screening platform employs a previously described unique method designed to determine the mechanism of action of an antibiotic drug. In the course of the study, we discovered a class of small molecules -- 2-pyrazol-1-yl-thiazole derivatives -- with the capacity to inhibit a strain of E. coli known as ΔTolC E. coli," Aladinskaya explained. "These research findings are a starting point for further investigation of this chemotype, including its subsequent structural optimization."

The study identified 688 substances with marked antibacterial activity. Thirty-eight molecules sharing the 2-pyrazol-1-yl-thiazole scaffold were found to be highly active against ΔTolC E. coli, indicating the potential value of this class of compounds. Interestingly, it was the first time this property was ever observed. As a result, the scientists selected eight compounds that inhibited protein synthesis and measured their toxicity to cells. One of the compounds had an optimal balance between its cytostatic and antibacterial properties.

Thanks to the new method, which enables rapid and effective screening of vast numbers of substances, a novel class of compounds with antibacterial activity was identified. Plans are underway to study their properties against antibiotic-resistant strains.

The focus of the Medicinal Chemistry and Bioinformatics Lab, led by Yan Ivanenkov, is on the development of small medicinal molecules using the latest methods in chemo- and bioinformatics. It is one of a handful of Russian laboratories directly and actively engaged in the development of innovative medicinal molecules. Some of them are currently on clinical trials in the U.S. and elsewhere, while others are being assessed in preclinical research. Among them are the prokaryotic translation inhibitors (antibacterial medicinal molecules) developed in collaboration with the Belozersky Institute of Physico-Chemical Biology and DHMEQ.

Another research focus of the laboratory is the creation of specialized mathematical algorithms and computer programs. As of today, six unique computer programs have been created for solving various problems in the fields of medicinal chemistry and chemoinformatics. Major pharmaceutical companies, including ChemDiv Novartis, Sanofi, Merck, Bayer, Pfizer, and Takeda, have commissioned research at the laboratory.